

Catalog# BP-50550

Alemtuzumab Biosimilar, Human CD52 Monoclonal Antibody

Alemtuzumab Biosimilar uses the same protein sequences as the therapeutic antibody alemtuzumab.

Alemtuzumab is a medication used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. In CLL, it has been used as both a first line and second line treatment. In MS it is generally only recommended if other treatments have not worked. It is given by injection into a vein. It is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived. After treatment with alemtuzumab, these CD52-bearing lymphocytes are targeted for destruction.

| Product Details | |
|------------------------|--|
| CAS No. | 216503-57-0 |
| Species Reactivity | Human |
| Source | Mammalian cells |
| Isotype | Human IgG1 kappa |
| Class | Monoclonal |
| Type | Antibody |
| Clone | Alemtuzumab Biosimilar |
| Conjugate | Unconjugated |
| Immunogen | Human CD52, a protein present on the surface of mature lymphocytes |
| Purity | >95% |
| Molecular Weight | 146.06 kDa |
| Protein Concentration | 1 mg/ml |
| Formulation | 0.2 μ M filtered PBS solution, pH 7.4 |
| Storage conditions | 4°C for short time, -20°C or -80°C for long time. |